Biotech firm Enveda raised $311M at a $2 billion valuation to advance nature-derived drugs. Current clinical trials focus on skin conditions and weight loss maintenance following GLP-1 use.
HOW THIS AFFECTS YOU
●
investorYou should watch the scale of capital flowing into AI-native biotech platforms.
●
healthYou can expect new therapeutic options for skin health and metabolic management from AI-driven research.